Biotech | August 08, 2021
Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr
The company expects revenue growth of 10-15 per cent in the US
The company expects revenue growth of 10-15 per cent in the US
PAT rises to Rs 195.76 crore
The transaction is expected to close in the Q4FY22
India business contributes to a stellar performance
Forex gains stood at Rs 20 crore for the quarter
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Ibuprofen and Famotidine Tablets is an AB-rated generic therapeutic equivalent version of Horizon Medicines LLC’s Duexis Tablets, 800 mg/26.6 mg
Advances deployment of mRNA technology across vaccines and therapeutics development
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
Subscribe To Our Newsletter & Stay Updated
